For example, it has been demonstrated that GLP-1 receptor agonists and SGLT-2 inhibitors, in addition to their ability to lower glucose levels, have the potential to enhance atherogenic dyslipidemia and decrease cardiovascular events in individuals diagnosed with type 2 diabetes [9,10]. Here, GLP1R is linked to type 2 diabetes mellitus.